Abstract
Objective We aimed to assess health-related quality of life (HRQOL) in a cohort of very preterm born children and adolescents (aged 5-16), and to compare it with their fullterm born siblings and the general population. We also explored correlates of HRQOL among the very preterm born.
Design Cross-sectional survey
Patients Children born <32 weeks gestation (N = 442) as well as their fullterm born siblings (N = 145)
Main outcome measures Primary outcome was KINDL total score (0 worst - 100 best), a validated multidimensional measure of HRQOL in children and adolescents.
Methods Linear mixed models accounted for family unit. Secondary analysis compared very preterm born children to another cohort of healthy children from the same time period. A classification tree analysis explored potential correlates of HRQOL.
Results On average, preterm children, both <28 and 28-31 weeks gestational age, had similar KINDL total score to fullterm sibling controls (-2.3, 95% CI -3.6 to -0.6), and to population controls (+1.4, 95% CI 0.2 to 2.5). Chronic non-respiratory health conditions (such as attention deficit hyperactivity disorder (ADHD) or heart conditions, but not including cerebral palsy), age, and respiratory symptoms affecting daily life were key correlates of HRQOL among very preterm born children.
Conclusions Very preterm birth in children and adolescents was not associated with a relevant reduction in HRQOL compared to their fullterm born peers. However, lower HRQOL was explained by other factors, such as older age, and the presence of chronic non-respiratory health conditions, but also by possibly modifiable current respiratory symptoms. The influence of respiratory symptom amelioration and its potential influence on HRQOL needs to be investigated further.
What is already known on this topic As infants born very preterm become more likely to survive, the importance of health-related quality of life (HRQOL) increases. Research on HRQOL in very preterm born children and adolescents often focuses on non-modifiable risk factors without potential interventions.
What this study adds HRQOL in very preterm born children and adolescents is similar to that of their siblings and to the general population. Age, respiratory symptoms, and chronic health conditions were associated with HRQOL. Better control of respiratory symptoms could improve HRQOL in very preterm born children and adolescents.
How this study might affect research, practice or policy A better understanding of the complex picture of pulmonary disease following prematurity throughout life and interventions to treat respiratory symptoms may be leveraged to improve HRQOL as very preterm born children and adolescents grow.
Competing Interest Statement
M. Adams receives a salary as network coordinator for the Swiss Neonatal Network. The other authors declare no conflicts of interest related to this work.
Funding Statement
The FLiP study received funding from LUNGE ZUERICH (#2020-06). Giancarlo Natalucci received funding from the Family Larsson-Rosenquist Foundation. We also acknowledge the support of the European Respiratory Society Fellowship Long-Term Research Fellowship 2020 (for Gabriela P Peralta). Ciao Corona is part of Corona Immunitas research network, coordinated by the Swiss School of Public Health (SSPH+), and funded by fundraising of SSPH+ that includes funds of the Swiss Federal Office of Public Health and private funders (ethical guidelines for funding stated by SSPH+ will be respected), by funds of the Cantons of Switzerland (Vaud, Zurich, and Basel) and by institutional funds of the Universities. Additional funding, specific to Ciao Corona, was received from the University of Zurich Foundation.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
FLiP: The study was approved by the Ethics Committee of the Canton of Zurich, Switzerland (2020--02396). Filling out the online survey was considered as providing consent. Ciao Corona: The Ciao Corona study was approved by the Ethics Committee of the Canton of Zurich, Switzerland (2020-01336). All participants provided written informed consent before being enrolled in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Minor changes to text, especially in the discussion.
Data Availability
Deidentified individual participant data (including data dictionaries) will be made available, in addition to study protocols, the statistical analysis plan, and the informed consent form. The data will be made available upon publication to researchers who provide a methodologically sound proposal for use in achieving the goals of the approved proposal. Proposals should be submitted to Susi Kriemler (susi.kriemlerwiget@uzh.ch).
